期刊
BRITISH JOURNAL OF HAEMATOLOGY
卷 117, 期 3, 页码 620-622出版社
BLACKWELL PUBLISHING LTD
DOI: 10.1046/j.1365-2141.2002.03499.x
关键词
chronic myeloid leukaemia; skin; Stevens-Johnson syndrome; STI571; tyrosine kinase inhibitor
类别
Between seven and 21% of patients treated with the specific tyrosine kinase inhibitor STI571 have been reported to develop mild-to-moderate severity of adverse cutaneous reactions. We report a patient in the blast crisis phase of chronic myeloid leukaemia who developed a life-threatening cutaneous reaction, Stevens-Johnson syndrome, following 1 week of STI571 therapy. This report may serve to remind the clinician about the possible severe cutaneous side-effects of STI571 before instituting more extensive clinical application of this agent in the future.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据